Brar Jyoti Eknoor, Nader Nader D
Division of Transplantation, Department of Surgery, University of Wisconsin at Madison , Madison, WI , USA and.
Immunol Invest. 2014;43(8):807-18. doi: 10.3109/08820139.2014.937492.
Very low early rejection rates and excellent short-term kidney allograft outcomes have been the mainstay of forwarding the field of Kidney Transplantation in the last few decades. This progress is mainly achieved by using the current armamentarium of maintenance immunosuppression in different combinations and dosages of calcineurin inhibitors (CNI), corticosteroids and antiproliferative drugs. Metabolic risks and nephrotoxicity of CNIs has led to a search for strategies to minimize their use. Similarly, metabolic risks, mood abnormalities and Cushing-like side effects of steroids have forced physicians and patients alike to try to minimize their use in transplantation. Here, we review the most recent randomized controlled trials of minimization of CNI/steroids in a manner (with incident immunologic risks, state of net immunosuppression and side- effects) that may be helpful to choose the best strategy for the individual patient. New trials testing minimization strategies should include in their design, an assessment of the impact of minimization on development of donor specific antibodies and antibody-mediated rejection as well as long-term outcomes.
在过去几十年里,极低的早期排斥率和出色的短期肾移植结果一直是推动肾移植领域发展的主要支柱。这一进展主要是通过使用目前的维持免疫抑制手段,即不同组合和剂量的钙调神经磷酸酶抑制剂(CNI)、皮质类固醇和抗增殖药物来实现的。CNI的代谢风险和肾毒性促使人们寻求尽量减少其使用的策略。同样,类固醇的代谢风险、情绪异常和类库欣样副作用也迫使医生和患者都试图在移植中尽量减少其使用。在此,我们以一种(考虑到免疫风险事件、净免疫抑制状态和副作用)可能有助于为个体患者选择最佳策略的方式,回顾了最近关于减少CNI/类固醇使用的随机对照试验。测试减少策略的新试验应在其设计中纳入对减少使用对供体特异性抗体的产生和抗体介导的排斥反应以及长期结果的影响的评估。